ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...

Streeting said his June 10-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

With an increasing demand for NHS services, technology is being positioned as a critical tool in eliminating inefficiencies ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...